ArticleRSC pharmaceutics2026
Comparative evaluation of USP II, USP IV, TIM-2, and the dynamic colon model as surrogates for human colonic drug dissolution.
Article in RSC pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study compares conventional dissolution apparatuses (USP II and IV) with advanced biorelevant models (TIM-2 and the Dynamic Colon Model, DCM) for assessing colonic drug dissolution. Theophylline dissolution from modified-release Uniphyllin Continus® tablets was evaluated across varying hydrodynamic conditions, with the DCM serving as a physiologically validated benchmark. Dissolution was highly dependent on USP II paddle speed (50-200 rpm). In the USP IV increasing flow rate (4-50 mL min
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.